Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29153
Title: | Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: Final 5-year efficacy and safety results from the FUTURE 1 phase 3 trial | Authors: | Tahir, Hasan Mease, Philip J. Kavanaugh, Arthur Reimold, Andreas Rech, Juergen Hall, Stephen GEUSENS, Piet Pellet, Pascale Delicha, Eumorphia Maria Pricop, Luminita Mpofu, Shephard |
Issue Date: | 2019 | Publisher: | OXFORD UNIV PRESS | Source: | RHEUMATOLOGY, 58(S3), p. 151-151 | Notes: | [Tahir, Hasan] Barts Hlth NHS Trust, Rheumatol, London, England. [Mease, Philip J.] Swedish Med Ctr, Dermatol, Seattle, WA USA. [Mease, Philip J.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, Arthur] Univ Calif La Jolla, San Diego Sch Med, La Jolla, CA USA. [Reimold, Andreas] Dallas Vet Affairs Med Ctr, Dallas, TX USA. [Reimold, Andreas] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Rech, Juergen] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol, Erlangen, Germany. [Hall, Stephen] Emeritus Res, Rheumatol, Camberwell, Australia. [Geusens, Piet] Univ Hasselt, Rheumatol, Hasselt, Belgium. [Pellet, Pascale; Mpofu, Shephard] Novartis Pharma AG, Immunol & Dermatol, Basel, Switzerland. [Delicha, Eumorphia Maria] Novartis Pharma AG, Biostat, Basel, Switzerland. [Pricop, Luminita] Novartis Pharmaceut, Immunol Hepatol & Dermatol Franchise, E Hanover, NJ USA. | Document URI: | http://hdl.handle.net/1942/29153 | ISSN: | 1462-0324 | e-ISSN: | 1462-0332 | ISI #: | 000478086100203 | Category: | M | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Show full item record
WEB OF SCIENCETM
Citations
1
checked on Aug 5, 2024
Page view(s)
72
checked on Jul 28, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.